Array BioPharma announces FDA acceptance to review new melanoma drug applications

Array BioPharma announces FDA acceptance to review new melanoma drug applications

BOULDER -- Array BioPharma (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Applications (NDAs) to support use of the combination of... Read More

Wednesday September 13, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, encorafenib, binimetinib

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

BOULDER -- Array BioPharma (Nasdaq:ARRY) today announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) to support use of the combination of... Read More

Wednesday July 5, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, binimetinib, encorafenib

Array BioPharma, Pierre Fabre announce positive results for cancer drug

Array BioPharma, Pierre Fabre announce positive results for cancer drug

BOULDER -- Array BioPharma (Nasdaq: ARRY) and Pierre Fabre today jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS ( Co mbined L GX818 U sed with M EK162 in B RAF... Read More

Monday September 26, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, Keith T. Flaherty, encorafenib, binimetinib, Frederic Duchecesne, COLUMBUS

Array BioPharma closes agreement with Pierre Fabre to commercialize cancer products

Array BioPharma closes agreement with Pierre Fabre to commercialize cancer products

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) today announced closing a definitive agreement with France-based Pierre Fabre following approval of the agreement by the European Commission on... Read More

Monday December 21, 2015 0 comments Tags: Boulder, Array BioPharma, Pierre Fabre, binimetinib, encorafenib

Array BioPharma partners with Pierre Fabre to globally develop and market cancer drugs

Array BioPharma partners with Pierre Fabre to globally develop and market cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) and France-based Pierre Fabre are collaborating to globally develop and commercialize Arrays late-stage novel oncology products, binimetinib and... Read More

Tuesday November 17, 2015 0 comments Tags: Boulder, Array BioPharma, Pierre Fabre, Ron Squarer, binimetinib, encorafenib